Company: SMNR
Filing Date: 2025-08-12
Form Type: S-4/A
Source: 0001193125-25-178821
Chunk: 719

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-4/A
Chunk 719
---
 facts and circumstances including, but not limited to:

| • |     | the risks, costs and benefits to New Semnur; |

| • |     | the impact on a director’s independence in the event that the related person is a director, immediate family member of a director or an entity with which a director is affiliated; |

| • |     | the availability of other sources for comparable services or products; and |

| • |     | the terms available to or from, as the case may be, unrelated third parties or to or from employees generally. |

The policy requires that, in determining whether to approve, ratify or reject a related person transaction, New Semnur’s audit committee, or other independent body of the New Semnur Board, must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, New Semnur’s best interests and those of New Semnur’s stockholders, as New Semnur’s audit committee, or other independent body of the New Semnur Board, determines in the good faith exercise of its discretion. 451

### LEGAL MATTERS
The validity of the shares of Common Stock to be issued pursuant to the Merger Agreement will be passed upon by Winston & Strawn LLP, who has represented Denali in connection with the Business Combination. Paul Hastings LLP has represented Semnur in connection with the Business Combination. Maples and Calder (Hong Kong) LLP has represented Denali on matters of Cayman Islands law. Conyers Dill & Pearman has represented Semnur on matters of Cayman Islands law.

### EXPERTS
The consolidated financial statements of Denali Capital Acquisition Corp. as of December 31, 2024, and for the year then ended, and the adjustments necessary to restate the 2023 segment information and to reflect the adoption of ASU 2023-07, Segment Reporting (Topic 280) to the 2023 segment information, as provided in Note 9, appearing in this proxy statement/prospectus, have been audited by Marcum Asia CPAs LLP, independent registered public accounting firm. The report of Marcum Asia CPAs LLP, appearing elsewhere herein, contains an explanatory paragraph expressing substantial doubt about the Company’s ability to continue as a going concern. The aforementioned financial statements are included herein in reliance upon the report of Marcum Asia CPAs LLP, given the authority of said firm as experts in accounting and auditing.

The consolidated financial statements of Denali